Tuesday, March 20, 2018
Company News: Page (1) of 1 - 02/22/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018

(February 22, 2018)

February 22, 2018

Breda, the Netherlands / Ghent, Belgium
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, March 1, 2018 at 3:00 pm CET (9:00 am ET) to discuss its 2017 financial results and provide a fourth quarter business update.  

To participate in the conference call, please select your phone number below, and use the confirmation code 6683242. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here. A replay of the webcast will also be available at the argenx website.

About argenxargenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.  


Dial-in numbers:
Please dial in 5-10 minutes prior to 3 p.m. CET/ 9 a.m. EDT using the number and conference ID below.

Confirmation Code: 6683242
Belgium                                0800 58228 
Belgium                                +32 (0)2 404 0659 
France                                  0805 101 219 
France                                  +33 (0)1 76 77 22 74 
Netherlands                       0800 023 1436 
Netherlands                       +31 (0) 20 721 9251 
United Kingdom                0800 358 6377 
United Kingdom               +44 (0)330 336 9105 
United States                    888-394-8218
United States                    +1 323-794-2149 

A question and answer session will follow the presentation of the results. Go to www.argenx.com to access the live audio webcast. The archived webcast will also be available (90 days) for replay shortly after the close of the call from the "Downloads" section of the argenx website.

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 243 40 70
[email protected]

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
[email protected]

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the encouraging clinical data; argenx's advancement of, and anticipated clinical development and regulatory milestones and plans; and the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in the final prospectus related to argenx's  U.S. public offering filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • New Alzheimer's Association Report Reveals Sharp Increases in Alzheimer's Prevalence, Deaths and Cost of Care
  • Global Incontinence and Ostomy Care Products Industry
  • Global Anti-Aging Products Industry
  • Brain Ischemia Market 2018 Progress | Size, Potential, Growth and Trend | A Definite Shift towards the Developing World | Forecasts till 2023
  • Refurbished Medical Equipment Market 2018 Global Analysis, Opportunities and Forecast To 2023

  • New Alzheimer's Association Report Reveals Sharp Increases in Alzheimer's Prevalence, Deaths and Cost of Care
  • Global Biopharmaceutical Bioseparation Systems Industry
  • CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
  • National Research Council contribution plays key role in newly approved Ebola vaccine
  • Twelve Global Startups Selected To Join New Innovation Platform, Plug and Play Cleveland

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines